Monalizumab vs Zimistobart

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: NKG2A · full Non-Small Cell Lung Cancer pipeline

Monalizumab

Developed by MedImmune LLC and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03822351 · Phase 2 · completed

Participants were randomized among three treatment arms, including 62 receiving durvalumab plus monalizumab and 67 receiving durvalumab alone, but the study was open-label rather than blinded. The primary clinical endpoint, RECIST 1.1 objective response at 16 weeks, was 40.3% with monalizumab plus durvalumab versus 23.9% with durvalumab alone; because statistical significance for this comparison was not reported, the result is considered unclear.

Next expected readout: January 2027 · NCT05221840 (registry estimate)

Reported efficacy

Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint): Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint): Control Arm (Durvalumab Monotherapy) 23.9% (95% CI 14.3-35.9) vs Arm A (Durvalumab + Oleclumab) 35.0% (95% CI 23.1-48.4) vs Arm B (Durvalumab + Monalizumab) 40.3% (95% CI 28.1-53.6) (unclear)

Result source: NCT03822351

Zimistobart

Developed by Bristol-Myers Squibb

Phase 2 in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMonalizumabZimistobart
PFS, median19.8 vs 7.3vs Durvalumab Monotherapyn 62NCT03822351—Not reported
OS, median—Trial running · NCT05221840—Not reported
ORR40.3% vs 23.9%vs Durvalumab Monotherapywk 16 · n 62NCT03822351—Not reported
Duration of response, median23n 25NCT03822351—Not reported

PFS, median

Monalizumab
19.8 vs 7.3vs Durvalumab Monotherapyn 62NCT03822351
Zimistobart
—Not reported

OS, median

Monalizumab
—Trial running · NCT05221840
Zimistobart
—Not reported

ORR

Monalizumab
40.3% vs 23.9%vs Durvalumab Monotherapywk 16 · n 62NCT03822351
Zimistobart
—Not reported

Duration of response, median

Monalizumab
23n 25NCT03822351
Zimistobart
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Zimistobart: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Monalizumab: 3 of 4 rows · Zimistobart: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricMonalizumab
Dropout rate
51.6%Arm B (Durvalumab + Monalizumab)a
NCT03822351 · Phase 2 · combination
show 3 more results
—Durvalumab + Monalizumab
NCT03822351 · Phase 2 · combination
3.7%1500 mg
NCT03794544 · Phase 2 · registry result, not featured evidence
5%1500 mg + 750 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—Arm B (Durvalumab + Monalizumab)a
NCT03822351 · Phase 2 · combination
show 3 more results
—Durvalumab + Monalizumab
NCT03822351 · Phase 2 · combination
—1500 mg
NCT03794544 · Phase 2 · registry result, not featured evidence
—1500 mg + 750 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
—Arm B (Durvalumab + Monalizumab)a
NCT03822351 · Phase 2 · combination
show 3 more results
27.9%Durvalumab + Monalizumab
NCT03822351 · Phase 2 · combination
11.5%1500 mg
NCT03794544 · Phase 2 · registry result, not featured evidence
5%1500 mg + 750 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
cough 42.6%
asthenia 24.6%
pruritus 24.6%
NCT03822351 · Phase 2 · combination
show 2 more results
1500 mg
fatigue 23.1%
procedural pain 19.2%
asthenia 11.5%
NCT03794544 · Phase 2 · registry result, not featured evidence
1500 mg + 750 mg
constipation 10%
fatigue 10%
pruritus 10%
NCT03794544 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Monalizumab

ORR 40.3% (n=62) vs 23.9% (n=67) Durvalumab Monotherapy @ 16wk
responder rate · % of participants
NCT03822351 · Phase 2 · combination
Duration of Response 23 vs NA Durvalumab Monotherapy months
time to event · months
NCT03822351 · Phase 2 · combination
Disease Control 79% (n=62) vs 58.2% (n=67) Durvalumab Monotherapy
responder rate · % of participants
NCT03822351 · Phase 2 · combination
PFS 19.8 vs 7.3 Durvalumab Monotherapy months
time to event · months
NCT03822351 · Phase 2 · combination
PFS-12 73.2% (n=62) vs 37.6% (n=67) Durvalumab Monotherapy @ 52wk
responder rate · % of participants
NCT03822351 · Phase 2 · combination
Overall Survival NA vs 40.9 Durvalumab Monotherapy months
time to event · months
NCT03822351 · Phase 2 · combination
Major Pathologic 11.1% (n=27) @ 6wk1500 mg
responder rate · % of participants
No placebo or comparator arm
NCT03794544 · Phase 2 · registry result, not featured evidence
show 1 more result
30% (n=20) @ 6wk1500 mg + 750 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
Pathologic Complete 3.7% (n=27) @ 6wk1500 mg
responder rate · % of participants
No placebo or comparator arm
NCT03794544 · Phase 2 · registry result, not featured evidence
show 1 more result
10% (n=20) @ 6wk1500 mg + 750 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Monalizumab's landscape · Zimistobart's landscape